Trials / Unknown
UnknownNCT00515892
Safety Study of CAT-8015 Immunoxin in Patients With NHL With Advance Disease
A Phase 1, Multicenter, Dose Escalation Study of CAT-8015 in Patients With Relapsed or Refractory Non-Hodgkin'd Lymphoma (NHL)
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 50 (estimated)
- Sponsor
- Cambridge Antibody Technology · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
RATIONALE: The CAT-8015 immunotoxin can bind tumor cells and kill them without harming normal cells. This may be effective treatment for Non-Hodgkin's lymphoma (NHL) that has not responded to chemotherapy, surgery or radiation therapy. PURPOSE: Phase 1 dose escalation study to determine the maximum tolerated dose of CAT-8015 immunotoxin in treating patients who have Non-Hodgkin's lymphoma and do not respond to treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Immunotoxin therapy | |
| DRUG | CAT-8015 Immunotoxin | |
| PROCEDURE | Biological therapy | |
| PROCEDURE | Antibody Therapy | |
| PROCEDURE | Monoclonal Antibody Therapy |
Timeline
- Start date
- 2007-08-01
- First posted
- 2007-08-14
- Last updated
- 2007-08-14
Locations
3 sites across 2 countries: United States, Poland
Source: ClinicalTrials.gov record NCT00515892. Inclusion in this directory is not an endorsement.